SecBot SecBot
SECBOTREPLAY Home › Report › INO

INO · $80.5M equity offering closed

INOVIO PHARMACEUTICALS, INC. · 8-K filed Nov 9, 2026 at 07:30 ET

At the news

BEARISHIMPACT 5/10

8-K filed Nov 9, 2026 at 07:30 ET

Inovio Pharmaceuticals filed an 8-K reporting the entry into an underwriting agreement for a $75M public offering of 58.7M common shares and pre-funded warrants for 12.7M shares, with the underwriters exercising their option to purchase an additional 10.7M shares in full. Net proceeds are expected to be approximately $80.5M, which management believes will fund operations into late Q4 2027. The offering follows the recent FDA accelerated approval of VOCERYQ and comes just days after a prior 424B5 filing for the same $75M raise, confirming acute capital needs at a $150M market cap with massive dilution.

  • Priced 58,747,235 common shares at $1.05/share and 12,681,337 pre-funded warrants at $1.049/warrant
  • Underwriters exercised in full the 30-day option for 10,714,285 additional shares
  • Net proceeds expected to be approximately $80.5 million
  • Pre-funded warrants have an exercise price of $0.001 per share

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access